EUVIMEDEUVIMED entdecken
Fallbericht

Development of ANCA-associated vasculitis followed by SARS-CoV-2 vaccination in a patient with HLA-DRB1*09:01 allele

Takuro Kawamura iD, Daigo Nakazawa, Saori Nishio, Taiki Isozaki, Maki Komatsumoto, Tatsuya Atsumi

Modern Rheumatology Case Reports · 19.06.2023 · 7 (2) · 426-430

DOI: 10.1093/mrcr/rxac093 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, online erschienen am 05.01.2023. Verfasst von Takuro Kawamura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaidô, Japan. Hauptthemen laut MEDLINE: COVID-19, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents with severe pneumonia and fatal systemic complications. Currently, SARS-CoV-2 vaccines are effective in reducing the risk of new onset and getting worse of the disease. However, autoimmune diseases such as antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) have been reported to develop after COVID-19 vaccine administration. A 71-year-old woman presented with fever, malaise, urinary abnormalities, and renal dysfunction after receiving the COVID-19 vaccine (Pfizer-BioNTech). We clinically diagnosed AAV with her manifestations and serological test (myeloperoxidase-ANCA-positive). Her clinical findings were improved after immunosuppressive therapy. We examined her genetic susceptibility to AAV, and we found that her allele was HLA-DRB1*09:01, which is a risk allele of myeloperoxidase-AAV. Mechanistically, SARS-CoV-2 vaccines would activate immunity, including neutrophils, and trigger AAV onset in this patient with a genetic risk to develop AAV. The pathophysiology of this case would share with that of autoimmune/inflammatory syndrome induced by adjuvants in the absence of external adjuvants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisFemaleHumansAgedCOVID-19 VaccinesHLA-DRB1 ChainsPeroxidaseSARS-CoV-2AllelesAntibodies, Antineutrophil CytoplasmicVaccination

Stichwörter der Autor:innen

ANCA-associated vasculitisASIACOVID-19HLA-DRB1*09: 01 alleleSARS-CoV-2 vaccines

Substanzen

COVID-19 VaccinesHLA-DRB1 ChainsPeroxidaseAntibodies, Antineutrophil Cytoplasmic

Autor:innen und Institutionen

  • Department of Rheumatology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaidô, Japan.

ORCID-Profile: Takuro Kawamura

Zitieren

APA

Kawamura, T., Nakazawa, D., Nishio, S., Isozaki, T., Komatsumoto, M., & Atsumi, T. (2023). Development of ANCA-associated vasculitis followed by SARS-CoV-2 vaccination in a patient with HLA-DRB1*09:01 allele. Modern Rheumatology Case Reports, 7(2), 426-430. https://doi.org/10.1093/mrcr/rxac093

Vancouver

Kawamura T, Nakazawa D, Nishio S, Isozaki T, Komatsumoto M, Atsumi T. Development of ANCA-associated vasculitis followed by SARS-CoV-2 vaccination in a patient with HLA-DRB1*09:01 allele. Modern Rheumatology Case Reports. 2023;7(2):426-430. doi:10.1093/mrcr/rxac093

BibTeX
@article{Kawamura2023,
  author = {Kawamura, Takuro and Nakazawa, Daigo and Nishio, Saori and Isozaki, Taiki and Komatsumoto, Maki and Atsumi, Tatsuya},
  title = {Development of ANCA-associated vasculitis followed by SARS-CoV-2 vaccination in a patient with HLA-DRB1*09:01 allele},
  journal = {Modern Rheumatology Case Reports},
  year = {2023},
  volume = {7},
  number = {2},
  pages = {426--430},
  doi = {10.1093/mrcr/rxac093}
}
Kostenlos starten →